104 related articles for article (PubMed ID: 9298933)
21. Interleukin-1 modulatory effect on the action of chemotherapeutic drugs and localized irradiation of the lip, duodenum, and tumor.
Zaghloul MS; Dorie MJ; Kallman RF
Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):417-25. PubMed ID: 8514539
[TBL] [Abstract][Full Text] [Related]
22. Combined interleukin-1 beta/interleukin-6 treatment in mice: synergistic myelostimulatory activity and myelorestorative effect after cyclophosphamide-induced myelosuppression.
Tritarelli E; Greco G; Testa U; Belardelli F; Peschle C; Proietti E
Cancer Res; 1994 Dec; 54(24):6469-76. PubMed ID: 7987845
[TBL] [Abstract][Full Text] [Related]
23. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
Donnelly ET; Kelley M; Rockwell S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
[TBL] [Abstract][Full Text] [Related]
24. Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination.
Teicher BA; Holden SA; Eder JP; Herman TS; Antman KH; Frei E
Semin Oncol; 1990 Feb; 17(1 Suppl 3):18-32. PubMed ID: 2106164
[TBL] [Abstract][Full Text] [Related]
25. Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo.
Fujimoto S; Chikazawa H
Jpn J Cancer Res; 1998 Dec; 89(12):1343-51. PubMed ID: 10081496
[TBL] [Abstract][Full Text] [Related]
26. Synergistic interaction between cyclophosphamide or paclitaxel and the bioreductive compound NLCPQ-1, in vivo.
Papadopoulou MV; Ji M; Bloomer WD
Oncol Res; 2003; 13(12):561-6. PubMed ID: 12899246
[TBL] [Abstract][Full Text] [Related]
27. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
28. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
[TBL] [Abstract][Full Text] [Related]
29. Modulation of cisPlatin cytotoxicity by interleukin-1 alpha and resident tumor macrophages.
Braunschweiger PG; Basrur VS; Cameron D; Sharpe L; Santos O; Perras JP; Sevin BU; Markoe AM
Biotherapy; 1997; 10(2):129-37. PubMed ID: 9373735
[TBL] [Abstract][Full Text] [Related]
30. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
[TBL] [Abstract][Full Text] [Related]
31. Augmented growth inhibition of B16-BL6 melanoma by combined treatment with a selective matrix metalloproteinase inhibitor, MMI-166, and cytotoxic agents.
Hojo K; Maki H; Sawada TY; Maekawa R; Yoshioka T
Anticancer Res; 2002; 22(6A):3253-9. PubMed ID: 12530072
[TBL] [Abstract][Full Text] [Related]
32. Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial.
Logan TF; Jadali F; Egorin MJ; Mintun M; Sashin D; Gooding WE; Choi Y; Bishop H; Trump DL; Gardner D; Kirkwood J; Vlock D; Johnson C
Cancer Chemother Pharmacol; 2002 Dec; 50(6):433-44. PubMed ID: 12451469
[TBL] [Abstract][Full Text] [Related]
33. Antitumor effect of recombinant human interleukin-1 beta alone and in combination with natural human tumor necrosis factor-alpha.
Ohkura M; Fuchimoto S; Orita K
Jpn J Cancer Res; 1990 Oct; 81(10):1026-31. PubMed ID: 2121675
[TBL] [Abstract][Full Text] [Related]
34. Antitumor and immune-modulatory efficacy of dual-treatment based on levamisole and/or taurine in Ehrlich ascites carcinoma-bearing mice.
Ibrahim HM; Abdel Ghaffar FR; El-Elaimy IA; Gouida MS; Abd El Latif HM
Biomed Pharmacother; 2018 Oct; 106():43-49. PubMed ID: 29945116
[TBL] [Abstract][Full Text] [Related]
35. Dioscorea bulbifera polysaccharide and cyclophosphamide combination enhances anti-cervical cancer effect and attenuates immunosuppression and oxidative stress in mice.
Cui H; Li T; Wang L; Su Y; Xian CJ
Sci Rep; 2016 Jan; 5():19185. PubMed ID: 26753518
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of cancer chemotherapeutic efficacy of cyclophosphamide by Curculigo orchioides Gaertn and its ameliorative effects on cyclophosphamide-induced oxidative stress.
Murali VP; Kuttan G
Integr Cancer Ther; 2015 Mar; 14(2):172-83. PubMed ID: 25575532
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
[TBL] [Abstract][Full Text] [Related]
38. Combined use of insoluble β-glucan from the cell wall of Candida albicans and cyclophosphamide: Validation in S180 tumor-bearing mice.
Qi Y; Hu X; Cui J; Chen J; Wu Q; Sun X; Shi Y
Biomed Pharmacother; 2018 Jan; 97():1366-1372. PubMed ID: 29156526
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Holden SA; Herman TS; Epelbaum R; Pardee AB; Dezube B
Anticancer Res; 1991; 11(4):1555-60. PubMed ID: 1746913
[TBL] [Abstract][Full Text] [Related]
40. The synergistic antitumor effect of recombinant interleukin-1 and low-dose of cyclophosphamide in tumor-bearing mice.
Harada T; Kan N; Ichinose Y; Moriguchi Y; Li L; Sugie T; Okino T; Imamura M
J Surg Oncol; 1994 May; 56(1):39-45. PubMed ID: 8176939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
